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Abstract: Methadone has the potential to assist in the management of pain in children with
life-limiting illness, but its use is limited by its complex pharmacokinetic profile and limited research
on its use in children. This is a retrospective review of the use of methadone as an analgesic
in 16 children with life-limiting illness. Efficacy, dosing and side effect profile were analysed.
Fifteen (94%) patients had improvements in their analgesia with minimal observed adverse effects.
Patients were either rapidly converted from a prior opioid in one change or received methadone as
an adjunct medication. Conversions were calculated using ratios frequently in the range of 10:1 to
20:1 from the oral morphine equivalent total daily dose (MEDD). Adjunct initial dosing was a low
dose trial, often beginning with 1 mg at night. Only two patients required a dose adjustment due
to side effects attributed to methadone. This was despite the cohort having significant underlying
illnesses, extensive concurrent medications, and high methadone dosing where needed. Analysis of
dosing and ratios indicates that an individualised approach is required. Based on this and on the
infrequency of methadone use in this population, specialist assistance with dosing is recommended.
Further research, including prospective and pharmacokinetic studies, is recommended.
Keywords: methadone; analgesia; life-limiting; children; paediatric; opioid
1. Introduction
Methadone is a long-acting lipid soluble synthetic opioid analgesic frequently used in adult
palliative care, and increasingly in paediatrics. Methadone is generally used when other opioid
analgesic agents have failed to achieve sufficient analgesia or are causing excessive side effects. Due to
the presence of inactive metabolites with methadone it is well tolerated in renal failure and avoids
the anti-analgesic or potentially hyper-analgesic metabolites seen with morphine [1,2]. Efficacy is also
maintained in stable liver disease [2].
Methadone acts primarily at mu receptors but also serotonin, noradrenaline and
N-Methyl-D-aspartic acid (NMDA) receptors. Consequently, it may be associated with less sedation
and development of tolerance [3–5]. It is also a lower cost option compared to other opioids in
the American and Australian contexts [2]. Routes of administration can include oral, rectal, nasal,
sublingual, subcutaneous, epidural or intravenous [6]. The half-life of methadone varies significantly
between individuals and over time, and is shorter in children, [7–9]. With chronic administration
the half-life in adults drops from 54.8 h to 24 h [10]. It can take 4 to 10 days to achieve a steady
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state, and most deaths attributed to methadone overdose occur in the first 4 to 6 days of commencing
treatment due to this potential for accumulation [2].
Methadone has the potential for significant respiratory depression and prolongation of the
interval between the start of the Q wave and the end of the T wave (QT interval). Methadone
pharmacokinetics can also be altered by concurrent use of medications that access CYP3P4A or
CYPP2B6. This includes corticosteroids, fluconazole, erythromycin, ketoconazole, amitriptyline,
carbamazepine and phenytoin [2,11]. There are also social barriers to the use of methadone, including
stigmatization related to its use in addiction medicine [12,13].
Methadone is the oral analgesic of choice in Finland for paediatric palliative care, and is
used in paediatric persistent pain in Israel, however the literature base in paediatric populations
is limited [14,15]. Case series have shown methadone to be effective in paediatric pain management
related to surgery, cancer and sickle cell disease [3,11,12,15,16]. In paediatric oncology patients, it has
been found to be beneficial in managing vincristine-induced neuropathy and at end of life [11,16].
An important study by Davies et al. found pain management was improved by parental report in 16 of
17 children aged 2 to 18 years with advanced cancer when trialed on methadone [12]. Another study
in oncology patients found methadone was effective for analgesia in 64.3% of participants of average
age 15.7 years (range 0.6–23) [16]. It is also helpful in the management and prevention of opioid
withdrawal in children [16].
One-off or initial dosing used in paediatric studies generally ranged from 0.15 to 0.3 mg/kg,
with one study reporting an intravenous loading dose of 0.6 mg/kg [7,17,18]. Another study suggested
a starting dose of 0.1 mg/kg every 6 to 8 h for opioid-naïve patients [15]. The largest initial dose
reported in an opioid-naïve patient was 20 mg [18].
Compared to other opioids where a simple ratio tool can be applied, methadone requires a graded
conversion ratio based on prior opioid exposure, due to its complex pharmacokinetics [2,12,19,20].
A low opioid exposure (low oral morphine equivalent total daily dose (MEDD) and shorter duration
of use) requires a relatively higher methadone conversion ratio, while a high exposure requires
a comparatively lower methadone conversion ratio. Therefore, a ratio of 1:1 for conversion from
morphine may be appropriate for an opioid-naïve patient but may lead to significant adverse effects
where high-dose opioids have been used prior [2]. A morphine-to-methadone conversion ratio of
20:1 has been suggested in both adults and children receiving more than 1000 mg of daily oral
morphine [2,20]. A ratio of 10:1 has been suggested if the daily oral dose of morphine is less than
1000 mg [12]. Some studies suggest that the maximum daily dose a patient should be commenced on
is between 50 and 60 mg of oral methadone [19,21].
There are three common strategies which have been described when commencing an opioid
rotation to methadone: ‘rapid conversion’, ‘three-day switch’ and ‘ad libitum’ [2,22]. A ‘rapid
conversion’ involves stopping the prior opioid completely while a conversion ratio guides replacement
methadone dosing. A ‘three-day switch’ involves titration of methadone dosing to effect and concurrent
decrease of the prior opioids over three days. Finally, the ‘ad libitum’ method uses the amount and
frequency of as-needed doses as a guide to subsequent regular dosing. Use of ‘ad libitum’ strategies in
children can be complicated by a patient’s inability to directly request medication due to developmental
limitations, and a need to observe standard inpatient restricted drug protocols. A systematic review
of these methods found rapid conversion to be the least effective and most likely to cause adverse
effects [22]. A previous paediatric study found similar success with both rapid and titrated conversion
“over a few days” [12]. Other systematic reviews have failed to demonstrate evidence of superiority of
any one method [23].
Side effects of methadone in children in prior studies have been minor in both oncology and
post-operative settings. Adverse effects have included somnolence, mild respiratory depression,
hallucinations, nausea and constipation [12,17]. With one-time doses, sixty-five children undergoing
operations had no major adverse events [8,18]. With longer duration of dosing, for mixed indications,
sedation was noticeable in approximately one quarter of patients in one study of 41 children [16].
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With higher doses of methadone (25 to 33 mg/kg/day) adverse events have included drowsiness,
hypotension, hypoventilation and central nervous system depression [11,18]. Chronic methadone
therapy for analgesia contributed to the development of severe obstructive sleep apnoea in one case
study [24]. A specific concern with methadone use in all populations has been the risk of changes
in cardiac physiology. Reversible alterations in QT interval have been noted in children receiving
methadone, with concurrent use of medications such as fluconazole [11]. Changes in QT interval length
have not reached a point of clinical relevance in paediatric studies, however, even in neonates and
with long duration of use [7,11,25]. Despite this, and recent changes to the intravenous formulation
that further reduce risk, it is recommended that family history is considered before initiation [26,27].
The current study reviews children with life-limiting illnesses (cancer and non-cancer) prescribed
methadone for analgesia, including at end of life. The outcomes of interest were efficacy for analgesia,
side effect profile and dosing regimens to achieve analgesia. This study aims to contribute to the
growing literature on the use of methadone for analgesia in paediatric patients with life-limiting illness.
2. Methods
All patients prescribed methadone for analgesia were identified from the palliative care database
covering one tertiary children’s health service in Brisbane, based at the Royal Children’s Hospital from
2008 to 2014, and the Lady Cilento Children’s Hospital from 2014 to 2015, after the former ceased
operations. The focus of the study was children with both complex pain and serious, life-limiting illness.
Patients given methadone exclusively to assist with weaning opioids following Paediatric Intensive
Care Unit (PICU) admission, and not for analgesia, were excluded from the audit. A retrospective chart
audit was undertaken for the 11 patients identified through the database. Five additional cases eligible
for inclusion in the study were identified prospectively, resulting in a total of 16 patients included in
the audit. The current study was approved by Children’s Health Queensland Human Research and
Ethics Committee (HREC/12/QRCH/11, 12 January 2012).
Demographic data identified included the patient’s age, sex and underlying diagnosis.
Pain characteristics and prior treatments were documented, including the analgesic regimen
administered immediately prior to commencing methadone. Assessments of pain severity were
based on documented parental report, clinician review and self-report, as appropriate. Documented
regular medications given concurrently with methadone and side effects attributed to methadone were
also reviewed.
An equivalent total daily dose of oral morphine (MEDD) was calculated for each patient to
allow easier comparison and analysis. A paediatric source [28] was used to advise best equivalency,
supplemented with other sources where needed [29]. An oral-to-intravenous ratio of 3:1 was used for
morphine, and a conservative 2:1 oral-to-intravenous ratio of was used for methadone. The MEDD
was calculated based on the total scheduled dosing of prior opioids received in 24 h only, breakthrough
dosing was not included in this calculation. Table 1 shows the opioid equivalencies used to calculate
the MEDD [29].
Table 1. Conversion ratios used (parenteral form).
Morphine Fentanyl Hydromorphone
Relative Potency 1 40 5
Example Doses 4 mg 100 mcg 800 mcg
3. Results
Sixteen children were administered methadone over an 8-year period for analgesia in the context of
various life-limiting illnesses. Demographic details are listed in Table 2. Most patients had cancer (12 of
16, 75%), 3 had neurological diagnoses (19%) and 1 had a cardiac diagnosis (6%). There was an even
distribution of male and female patients. Patients ranged in age from 1.3 to 16 years (mean 7.4 years).
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Table 2. Patient demographics.
Patient Age Sex Weight (kg) Diagnosis Prior Opioid/Analgesia Care Location Goals of Care ECG
1 4 years F 19.0 Relapsed biliary embryonalrhabdomyosarcoma Hydromorphone Hospital (ward) Palliative Care Yes
2 2 years M 12.7 Haemophagocytic lymphohistiocytosis Hydromorphone, ketamine Hospital (ward) Pain Management No
3 8 years F 27.0 Relapsed acute lymphoblastic leukaemia Hydromorphone, ketamine Hospital (intensive care) Palliative Care Yes
4 3 years M 14.5 Metastatic hepatoblastoma Hydromorphone Hospital (ward) Pain Management No
5 5 years M 21.0 Relapsed acute lymphoblastic leukaemia Hydromorphone Home Palliative Care No
6 16months M 11.0
Meningococcal septicaemia with brain
injury and four limb amputation Morphine Hospital (ward) Pain Management No
7 12 years M 34.6 Relapsed pelvic alveolarrhabdomyosarcoma Hydromorphone Home Palliative Care No
8 9 years F 45.9 Frontotemporal pleomorphicxanthoastrocytoma Hydromorphone Hospital (ward) Pain Management No
9 16 years M 46.0
Refractory graft versus host disease post
bone marrow transplant for acute
myeloid leukaemia
Hydromorphone Hospital (ward) Palliative Care No
10 16 years M 38.6 Cerebral palsy with spastic quadriplegia,parental nutrition Fentanyl patch Hospital (ward) Palliative Care No
11 6 years F 20.0 Low grade sarcoma Hydromorphone Hospital (ward) Pain Management No
12 5 years F 18.0 Juvenile myelomonocytic leukaemia, graftversus host disease Hydromorphone, ketamine Hospital (intensive care) Pain Management Yes
13 7 years F 25.8 Epileptic encephalopathy Oxycodone Home Pain Management No
14 7 years F 22.0
Pulmonary atresia with ventricular septal
defect and major aortopulmonary
collateral arteries
Morphine Home Palliative Care No
15 15 years F 45.0
Severe veno-occlusive disease and renal
impairment post bone marrow transplant
for acute lymphoblastic leukaemia
Hydromorphone Hospital (intensive care) Pain Management Yes
16 23months M 15.0
Bi-lineage leukaemia requiring bone
marrow transplant Hydromorphone Hospital (intensive care) Pain Management Yes
ECG: refers to whether a recent ECG (electrocardiogram) was available at the time of commencing methadone.
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All patients had either overt reported pain or symptoms interpreted by parents and clinicians
to be indicative of pain. In six (38%) of the patients, pain was determined by proxy because the
patient was either developmentally incapable (through impairment or age) of verbal expression or
too unwell to communicate. Findings documented at review of children with pain most commonly
mentioned generalised distress (69%), variably documented as “distress”, “irritability”, “agitation” or
being “unsettled”. Other common findings associated with pain were decreased mobility (19%) and
decreased sleep (19%), with some patients displaying more than one of these features.
Nine patients received methadone for pain management (where goals of care still included disease
modification or cure). Seven patients received methadone in a palliative care context (where goals of
care were primarily comfort-focused, often at end of life) (See Table 2). All patients had methadone
commenced by the same consultant who specialised in palliative care, and also regularly managed
non-palliative patients with cancer and non-cancer pain.
The MEDD used at the time of commencing methadone, and the methadone dose (initial
and highest) are displayed with the demographic details in Table 3, illustrating the frequency of
high opioid dosing prior to methadone administration. Methadone was found to be generally well
tolerated and safe. Of the 16 patients reviewed, 15 (94%) continued the medication and had improved
outcomes determined either through improved pain or reduced requirement of other analgesia such
as breakthrough medications. One patient discontinued methadone due to perceived lack of effect.
Adverse symptoms in the early phase of treatment, summarised in Table 3, included drowsiness,
unsteadiness, itch, constipation, transient bradypnoea and behavioural change. One patient
experienced a seizure, for which methadone was considered as one of several potential pharmacological
causes, in the setting of complex multi-system disease. Three patients experienced signs of withdrawal,
including rebound pain and labile emotions, when methadone dosing or absorption was reduced.
In two patients, the dose of methadone was reduced due to adverse symptoms attributed to methadone
(unsteadiness and a minor head injury caused by a fall).
Of the patients reviewed, nine patients have subsequently died. All deaths were expected. Four of
these patients died within 16 days of commencing methadone, and three of those patients had been
on high-dose opioids prior to commencing methadone, using the previously established definition
of high dosing as dosing above 3 mg/kg/h of intravenous morphine equivalent [30]. Five patients
showed clinical improvement or stabilisation of their symptoms and were subsequently successfully
weaned off methadone. For two patients, methadone has been weaned without cessation at completion
of review.
Medications administered concurrently when methadone was commenced were reviewed as part
of this study. It was noted that in several cases these medications included those medications with
the potential to cause QTc prolongation [31]. Not all patients had an electrocardiogram (ECG) prior to
commencement, particularly where the patient was at end of life. The list of concurrent medications
included alternate analgesic medications, antibiotics, anti-seizure medications, anti-emetics, steroids
and other targeted treatments for underlying conditions. Planned concurrent chemotherapy agents
were not considered. Many of the patients required extensive concurrent medications for optimal
management, due to severity of illness or symptomatology.
Two cohorts emerged within the group of children analysed. One group of children were given
methadone as a complete replacement for other opioids (n = 12). This occurred in a situation where
high-dose opioids had preceded the change to methadone (see Table 3). Another group of children
were given methadone as an adjunct analgesic for difficult-to-manage pain (n = 3). This latter group
of children often subsequently transitioned to methadone as a primary opioid over days or weeks.
One child commenced methadone de novo, the only occasion where dosing was wholly based on
patient weight.
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Table 3. Summary of methadone usage.
Pt Approx.MEDD (PO)
Methadone
Starting Dose
and Route
Maximal Methadone
Dose and Route
Rapid
Conversion
or Adjuvant
Reason for Rotation
to Methadone
Conversion
Ratio (PO
Morph: PO
Meth)
Breakthrough
Analgesia
Side Effects or
Issues Noted Outcome
1 504 mg 5 mg QID PO
15 mg PO QID.
Rapid
conversion
Increasing
Drowsiness and
Inadequate Analgesia.
25:1
Hydromorph PCA IV. Less drowsy on
methadone. Able to
start walking again.
Withdrawal
symptoms.
Died 6 months after
commencing
methadone.Changed to 30 mg IV
infusion over 24 h
Changed to meth PCA
IV subsequently
2 1080 mg 1 mg nocteNG 2 mg QID SL Adjuvant
Loss of central
venous access and
unable to maintain
SC route.
N/A Hydromorph PCA andketamine IV
Drowsiness and
low respiratory rate
requiring doses to
be skipped.
Died 3 months after
commencing
methadone.
3 5400 mg 15 mg QID PO 240 mg IV infusionover 24 h
Rapid
conversion
Inadequate
Analgesia. 90:1
Hydromorph PCA
IV.Eventually
converted to meth
PCA IV
Improved
Analgesia.
Died one month
after commencing
methadone.
4 12 mg 1.5 mg QIDPO
3 mg TDS PO.
Changed to Fentanyl
patch
Rapid
conversion
Side effects with
morphine—inadequate
analgesia and itch.
Methadone only
alternative slow
release opioid that
comes as elixir.
2:1 Hydromorph NCA
Unsteadiness
attributed to
methadone.
Died 3 months after
ceasing methadone.
5 6000 mg
150 mg SC
infusion over
24 h
150 mg SC infusion
over 24 h
Rapid
conversion
Inadequate
Analgesia. 20:1 Meth SC
Improved
analgesia.
Died 7 days after
commencing
methadone.
6 96 mg 5.5 mg QIDNG 5.5 mg QID NG
Rapid
conversion Irritability. 4.4:1 Morph NCA IV
Withdrawal
symptoms.
Weaned off
methadone. Alive.
7 9000 mg
180 mg SC
infusion over
24 h
324 mg daily SC
infusion
Rapid
conversion
Inadequate
Analgesia. 25:1 Meth SC
Improved
analgesia.
Died 30 h after
methadone
rotation.
8 648 mg 15 mg QID PO 15 mg QID PO Rapidconversion
Inadequate
Analgesia. 10.8:1 Hydromorph PCA IV
No significant
improvement in
analgesia.
Weaned off
methadone. Alive.
9 10,800 mg
36 mg IV
infusion over
24 h
600 mg IV infusion
over 24 h
Rapid
conversion Myoclonus. 150:1 Meth PCA IV Less mycolonus.
Died 4 days after
methadone
rotation.
Children 2018, 5, 86 7 of 13
Table 3. Cont.
Pt Approx.MEDD (PO)
Methadone
Starting Dose
and Route
Maximal Methadone
Dose and Route
Rapid
Conversion
or Adjuvant
Reason for Rotation
to Methadone
Conversion
Ratio (PO
Morph: PO
Meth)
Breakthrough
Analgesia
Side Effects or
Issues Noted Outcome
10 288 mg 1 mg IVNOCTE 10 mg QID SL
Adjuvant.
Gradual
conversion to
methadone
Inadequate analgesia. N/A NCA fentanyl IV Improvedanalgesia.
Weaning
Methadone. Alive.
11 30 mg 0.5 mg QIDPO 2.5 mg TDS PO Rapidconversion
Inadequate analgesia.
Methadone syrup
available as elixir.
15:1 PCA hydromorph IV
Improved analgesia.
Episode of
drowsiness and
reduced RR (did
not require
naloxone).
Able to wean
methadone. Alive.
12 1080 mg 1 mg IVNOCTE 10 mg QID SL
Adjuvant for
one week,
then total
conversion to
methadone
Inadequate analgesia.
Seizures
(neurotoxicity)
possibly due to
hydromorphone.
N/A NCA hydromorph IV Improved analgesia.No further seizures.
Weaned off
methadone. Alive.
13
Not on
regular
opioid, but
having PRN
codeine
2 mg BD PO 4 mg QID PO
Commenced
as primary
pain
management
(de novo) at
0.1 mg/kg bd
Complex pain.
Neuropathic pain.
Dose based on
weight PRN oxycodone PO No improvement.
Weaned off
methadone. Alive.
14 120 mg
1 mg at night
for 1 day and
then 3 mg
QID SL
10 mg QID SL
Initially
adjuvant and
then rapid
conversion
Neurotoxicity. Severe
dysponea. Chest pain.
Required elixir.
10:1 PRN morph PO
Less confusion.
Improved analgesia
and less dyspnoea.
Alive.
15 1068 mg
36 mg IV
infusion over
24 h
72 mg IV infusion
over 24 h
Rapid
conversion
Inadequate Analgesia.
Agitation. 15:1 Meth NCA IV
Improved analgesia
and sedation.
Died 16 days after
methadone
rotation.
16 21 mg 0.5 mg TDSPO 0.5 mg TDS PO
Rapid
conversion
Available as elixir.
Experienced pruritis
with morphine.
14:1 PRN meth PO Stable analgesia.
Weaned methadone.
Died 3 weeks after
methadone ceased.
Abbreviations: IV, Intravenous; PO, Per Os/Oral; SC, Subcutaneous; SL, Sublingual; NG, Nasogastric; PRN, Pro Re Nata/Medication prescribed on an ‘as-needed’ basis;
NCA, Nurse-controlled analgesia; PCA, Patient-controlled analgesia; TDS, Ter Die Sumendum/Medication administered three times per day; QID, Quarter In Due/Medication
administered four times per day, Nocte Medication administered at night; Morph, Morphine; Meth, Methadone; Hydromorph, Hydromorphone; N/A, not applicable (where initial
methadone dosing was not a rapid conversion from alternate opioid).
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The most common reason for a change to methadone (n = 9) was incomplete analgesia while on
other opioids. This was often morphine or hydromorphone given at a high dose. Other reasons for
rotation to methadone included side effects from other opioids (n = 6) and a desire to use oral analgesic
medications (n = 3). For some patients, the change to methadone was multi-factorial.
Routes of administration included enteral (n = 8), sublingual (n = 2), intravenous (n = 4) and
subcutaneous (n = 2). Twelve children were rapidly converted from a prior opioid to methadone and
conversion ratios from equivalent daily oral morphine equivalent ranged from 2:1 to 150:1. Half of the
conversions to methadone were in the range 10:1 to 20:1, two received less than 10:1, and four received
greater than 20:1. The lowest conversion ratio of 150:1 correlates with the highest equivalent prior
MEDD (10,800 mg) of the patients analysed. This patient subsequently needed incremental dosing
up to 600 mg daily of infused subcutaneous methadone, representing a conversion of 13:1 from the
original morphine equivalent, in the context of end-of-life care. A graph of conversion ratio to MEDD
prior to conversion is provided with an average line on a logarithmic scale (Figure 1), demonstrating
an expected increase in ratio used with increased previous opioid exposure.
Children 2018, 5, x FOR PEER REVIEW  8 of 13 
 
Routes of administration included enteral (n = 8), sublingual (n = 2), intravenous (n = 4) and 
subcutaneous (n = 2). Twelve children were rapidly converted from a prior opioid to methadone and 
conversion ratios from equivalent daily oral morphine equivalent ranged from 2:1 to 150:1. Half of 
the conversions to methadone were in the range 10:1 to 20:1, two received less than 10:1, and four 
received greater than 20:1. The lowest conversion ratio of 150:1 correlates with the highest equivalent 
prior MEDD (10,800 mg) of the patients analysed. This patient subsequently needed incremental 
dosing up to 600 mg daily of infused subcutaneous methadone, representing a conversion of 13:1 
from the original morphine equivalent, in the context of end-of-life care. A graph of conversion ratio 
to MEDD prior to conversion is provided with an average line on a logarithmic scale (Figure 1), 
demonstrating an expected increase in ratio used with increased previous opioid exposure. 
 
Figure 1. Logarithmic curve of methadone conversion ratios used for increasing MEDD prior to 
conversion. Only rapid conversion ratios considered for this graph. 
Where methadone was used as an adjuvant (n = 3), the starting dose was 1 mg at night 
intravenously or sublingually, in addition to the prior opioid used. These patients subsequently 
rotated to methadone as their regular opioid analgesic over a period of days to weeks. 
Analgesic strategies immediately prior to the introduction of methadone were most commonly 
hydromorphone infusions (10 patients), concurrent ketamine infusion with opioid infusion (six 
patients), concurrent benzodiazepines with opioid management (five patients), neuropathic agents 
(gabapentin, pregabalin or amitriptyline) (four patients), fentanyl infusion (two patients), oral 
opioids (codeine, morphine or oxycodone in three patients), morphine infusion (one patient) and 
dexmedetomidine infusion (one patient in PICU). The majority (56%) of patients were also accessing 
documented non-pharmacological strategies. The most common was music therapy (n = 5), followed 
by occupational therapy, physiotherapy, parent-led distraction, and acupuncture. 
4. Discussion 
Increasing the range of safe and effective methods of providing analgesia in children is 
important, particularly in life-limiting illness and at end of life. Methadone was infrequently used at 
1
10
100
1,000
1 10 100 1,000 10,000 100,000
M
ED
D:
TM
DD
MEDD prior to conversion
Trends in conversion ratios with increased opioid 
exposure prior
Figure 1. Logarithmic curve of methadone conversion ratios used for increasing MEDD prior to
conversion. Only rapid conversion ratios considered for this graph.
Where methadone was used as an adjuvant (n = 3), the starting dose was 1 mg at night
intravenously or sublingually, in addition to the prior opioid used. These patients subsequently
rotated to methadone as their regular opioid analgesic over a period of days to weeks.
Analgesic strategies immediately prior to the introduction of methadone were most commonly
hydromorphone infusions (10 patients), concurrent ketamine infusion with opioid infusion
(six patients), concurrent benzodiazepines with opioid management (five patients), neuropathic
agents (gabapentin, pregabalin or amitriptyline) (four patients), fentanyl infusion (two patients),
oral opioids (codeine, morphine or oxycodone in three patients), morphine infusion (one patient) and
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dexmedetomidine infusion (one patient in PICU). The majority (56%) of patients were also accessing
documented non-pharmacological strategies. The most common was music therapy (n = 5), followed
by occupational therapy, physiotherapy, parent-led distraction, and acupuncture.
4. Discussion
Increasing the range of safe and effective methods of providing analgesia in children is important,
particularly in life-limiting illness and at end of life. Methadone was infrequently used at the sites
involved in this study but was effective for analgesia and had a tolerable side effect profile in the
majority of cases reviewed. All patients in this study had alternate opioid medications for analgesia,
and many were on high-dose opioids, prior to commencing methadone. The majority had been on
an alternate opioid and a sedative infusion (midazolam, ketamine or dexmedetomidine) prior to
starting methadone. Methadone was effective even when children had been on significant analgesia
and sedation, sometimes requiring PICU support, prior to its commencement. These findings and
low subject numbers overall may indicate that methadone was a ‘last resort’ in analgesia in the
Queensland context.
In contrast to findings in one systematic review, the current study demonstrated tolerability and
efficacy of rapid conversion techniques [22]. In the current study, rapid conversion was indicated
for individual treatment needs, such as pain crisis or technical inability to continue increasing other
measures. It is possible some of the initial conversion ratios and nocte dosing of methadone in
the current audit were conceived as a longer-term conversion strategy with subsequent titration
of dosing expected. The current audit still assists in defining safe initial dosing with prior opioid
exposure though.
Review of dosing practices within this study shows that individualisation is needed. Figure 2
demonstrates the various approaches to commencing methadone used in the current study, and is a
guide based on our review of these cases and relevant literature. Where possible, we suggest that a
practitioner with experience in prescribing methadone is involved in the initiation of methadone as
an analgesic, and due care is exercised when initiating or rotating to methadone. Individual patient
factors such as goals of care, care setting and previous type and dose of opioids used need to be
considered in this process. Rotation to methadone should be seen as a “care pathway” rather than a
“dose calculation”.
The trend with commencement of methadone was either to add methadone to existing analgesic
regimens as an adjuvant, or to rapidly convert current opioids to methadone. This would also
include the discontinuation of ketamine. The ratios used to calculate an appropriate starting dose of
methadone varied, with ratios closer to 1:1 used for lower prior opioid exposure, and ratios around 20:1
to 25:1 where there had been higher prior opioid exposure. This is appropriate given the literature on
methadone’s complex pharmacokinetics. Where methadone was used as an adjuvant treatment, dosing
was generally 1 mg at night intravenously or orally. Based on the current audit, a suggested guide to
initial dosing is provided in Figure 2. Due to its prolonged half-life, dose titration after commencing
methadone should occur every three days where possible, with careful review and consideration of
side effects such as drowsiness.
Methadone administration route in this study was primarily related to patient practicalities,
for example, oral route for ongoing use with stable-phase disease and subcutaneous use at end of life.
Dosing intervals for oral therapy should be shorter than with adult patients based on difference in
pharmacokinetics and may need to become shorter over time [9,10]. Due to the challenges of individual
pharmacokinetics and a tendency to initially under-dose methadone [32], careful observation and
appropriate titration of methadone may be necessary. For this reason, it is often recommended that
patients be hospitalised during initial therapy. Research has found inpatient titration is faster [21].
In Davies’ study, 6 paediatric patients commenced methadone in the community, where there was
perceived parental reliability and provision for extra in-home monitoring including regular phone calls.
Only one of these patients subsequently required related admission for monitoring [12]. The specific
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dosing used in this setting was not provided. Studies in adult patients found outpatient titration
to be safe and effective [21]. In the current audit, 75% of patients (n = 12) commenced methadone
as an inpatient. However, inpatient admission in our context may be related to concurrent ongoing
treatments and remaining at home may be related to the goals of the child and family during end-of-life
care. If methadone is to be commenced at home, the parents need to be reliable in their ability to report
pain and side effects, and provision of significant in-home support must be possible.
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Due to significant poly-pharmacy related to complex underlying conditions and symptoms,
side effects patients experienced were possibly multi-factorial. Milder side effects possibly were
not documented in the context of severe underlying illness and related symptomatology. It is also
important to note that six of the patients had side effects from previous opioids significant enough to
require opioid conversion to methadone, whereas 15 of 16 patients then found methadone tolerable.
Although significant cardiac events were not noted with children in this study (despite three patients
receiving greater than 200 mg per day dosing, which is thought to offer significant electrophysiologic
risk [2]), consideration of whether to perform an ECG remains important and recommendations feature
in the guideline (Figure 2).
This retrospective audit was limited by the quality and quantity of documentation taken for each
child, although this was augmented by having the prescribing clinician review documentation as
well. Retrospective chart analysis with an outcome of “negative” or “positive” tone in records after
starting an intervention has previously been used in both paediatric methadone research and in other
medication research in paediatric palliative care [12,33]. Ideally a pre- and post-intervention pain score
should be used in future prospective analysis.
A recent review examined necessary dose alterations after commencing methadone in children,
to assess efficacy of initial dosing ratios used [34]. An issue with this approach is that at end of life
escalating pain is known to occur, and so necessary increments in dosing after commencement could
be due to initial under-dosing or may represent appropriate increases related to disease progression.
For these reasons, separate consideration of efficacy from initial dosing ratios was not undertaken in
the current study but would be an area of interest for future audits.
Three patients (19%) receiving end-of-life care with an underlying oncology diagnosis died within
7 days of commencing methadone. Previous studies have found use of opioids in palliative care does
not hasten death; these three deaths were attributed wholly to underlying disease processes [35–37].
5. Conclusions
Methadone contributed to effective analgesia in most paediatric patients with complex cancer and
non-cancer life-limiting diagnoses (94%; 15 of 16 patients). Methadone was generally well tolerated
despite significant disease burden and extensive concurrent medications. Methadone has the potential
to offer a promising alternative to other opioids in paediatrics. A guideline with suggested dosing
conversions from morphine equivalent is provided based on prior opioid exposure. This audit
will give clinicians greater confidence in prescribing methadone, particularly in terms of dosing
regimen. Greater confidence may lead to initiation of methadone earlier in the disease continuum
when appropriate, rather than it being used as a medication of “last resort”. Ongoing research is
required to assist in developing appropriate recommendations and guidelines for use of methadone as
an analgesic in children with life-limiting illness.
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